PLG and neoplasm: By inhibiting plasmin, TFPI-2 effectively decreases activation of MMP-1, MMP-3 and MMP-9 (Rao et al, 1999), and reduces the invasive potential of several tumour cell lines including A549, an NSCLC cell line (Lakka et al, 2000).